-
1 Comment
Q-linea AB (publ) is currently in a long term downtrend where the price is trading 6.8% below its 200 day moving average.
From a valuation standpoint, the stock is 12.6% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 1479.4.
Q-linea AB (publ)'s total revenue sank by 100.0% to $0 since the same quarter in the previous year.
Its net income has increased by 21.5% to $-49M since the same quarter in the previous year.
Finally, its free cash flow fell by 40.1% to $-78M since the same quarter in the previous year.
Based on the above factors, Q-linea AB (publ) gets an overall score of 1/5.
Sector | Healthcare |
---|---|
Exchange | F |
CurrencyCode | EUR |
ISIN | SE0011527845 |
Industry | Medical Devices |
Market Cap | 299M |
---|---|
PE Ratio | 0.0 |
Target Price | None |
Beta | 0.98 |
Dividend Yield | None |
Q-linea AB (publ) engages in the development of instruments and consumables for infection disease diagnostics in the United Kingdom. The company offers ASTar, an antimicrobial susceptibility testing technologies used in the treatment of bloodstream infections and sepsis. It also develops Podler, a portable blood culture unit for incubating and detecting growth in blood bottles. It serves to physicians, hospitals, laboratories, healthcare payers and the medical profession. The company was incorporated in 2007 and is headquartered in Uppsala, Sweden.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 3F8.F using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025